Semaglutide activates one receptor, GLP-1. Tirzepatide activates two, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), and that dual action is what sets it apart.
Working both pathways at once gives tirzepatide stronger appetite suppression, better insulin sensitivity and potentially wider metabolic benefits.
One way to picture it: semaglutide is a precise tool and tirzepatide a broader one, and both are effective. For more on the mechanisms, read how GLP-1 medications work.








